Diagnósticos da América (DASA3) reported on Monday, July 13, 2026, that the board of directors has approved the call for a digital Extraordinary General Meeting for August 3, 2026, at 2:00 p.m., to deliberate on the proposed merger of Patologia Clínica Dr. Geraldo Lustosa Cabral Ltda. (Lustosa), a company 100% controlled by the group, whose net assets were valued at R$ 16,216,172.63 on the base date of March 31, 2026.
The meeting agenda includes approval of the terms and conditions of the Merger Protocol and Justification, ratification of the appointment of Apsis Consultoria e Avaliações Ltda. as the independent valuation firm, approval of the valuation report of Lustosa’s net assets, and approval of the merger itself.
According to Dasa, completion of the transaction depends on shareholder approval of the matters at the meeting, and the merger will take effect on the date it is filed with the relevant commercial registry.
The company emphasized that the merger will not result in a capital increase, the issuance of new shares, or any change in the current shareholders’ ownership interests, since Dasa already holds 100% of Lustosa’s quotas and the investment is already reflected in the financial statements under the equity method. There will be no withdrawal rights for shareholders.
The documents related to the merger, including the Protocol and Justification, valuation report, management’s proposal, and remote voting ballot, are available on the Investor Relations websites of Dasa, the CVM, and B3.
